1. Cell Cycle/DNA Damage
    Cytoskeleton
    Antibody-drug Conjugate/ADC Related
  2. Microtubule/Tubulin
    ADC Cytotoxin

Monomethyl auristatin E (Synonyms: Vedotin; MMAE)

Cat. No.: HY-15162 Purity: 99.76%
Data Sheet SDS Handling Instructions

Monomethyl auristatin E (MMAE) is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin, and also shows inhibition of antibody-drug conjugates (ADCs) activity.

For research use only. We do not sell to patients.
Monomethyl auristatin E Chemical Structure

Monomethyl auristatin E Chemical Structure

CAS No. : 474645-27-7

Size Price Stock Quantity
10 mM * 1 mL in DMSO $332 In-stock
1 mg $90 In-stock
5 mg $210 In-stock
10 mg $310 In-stock
25 mg $690 In-stock
50 mg $960 In-stock
100 mg $1700 In-stock
200 mg $2650 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Monomethyl auristatin E:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Monomethyl auristatin E (MMAE) is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin, and also shows inhibition of antibody-drug conjugates (ADCs) activity.

IC50 & Target

Microtubule[1]

In Vitro

Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].

In Vivo

Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02388490 Seoul National University Hospital|Seoul National University Bundang Hospital|SMG-SNU Boramae Medical Center Relapsed or Refractory EBV-and CD30-positive Lymphomas August 2015 Phase 2
NCT01940796 Massachusetts General Hospital|Seattle Genetics, Inc. Graft-vs-Host Disease|GVHD October 2013 Phase 1
NCT02164006 TG Therapeutics, Inc. Hodgkin's Lymphoma June 2014 Phase 1
NCT03070990 Astellas Pharma Inc|Seattle Genetics, Inc. Metastatic Urothelial Cancer April 24, 2017 Phase 1
NCT01900496 Sidney Kimmel Comprehensive Cancer Center Lymphoma April 2014 Early Phase 1
NCT01841021 H. Lee Moffitt Cancer Center and Research Institute|Seattle Genetics, Inc. Peripheral T-Cell Lymphoma April 2014
NCT01492088 Millennium Pharmaceuticals, Inc.|Takeda Relapsed or Refractory Hodgkin Lymphoma|Relapsed or Refractory Anaplastic Large-cell Lymphoma April 16, 2012 Phase 1|Phase 2
NCT01990534 Millennium Pharmaceuticals, Inc.|Takeda Hodgkin Lymphoma March 2014 Phase 4
NCT01950364 Millennium Pharmaceuticals, Inc. Hodgkin Lymphoma|Anaplastic Large-cell Lymphoma November 2013 Phase 1
NCT02567851 University of Birmingham|Leukaemia Lymphoma Research|Millennium Pharmaceuticals, Inc. Hodgkin Disease February 2014 Phase 2
NCT02280785 Samsung Medical Center|Millennium Pharmaceuticals, Inc. Non-Hodgkin Lymphoma November 2014 Phase 2
NCT02588651 Deepa Jagadeesh|Case Comprehensive Cancer Center T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepato-splenic T-cell Lymphoma|Adult T-cell Leukemia/Lymphoma|Enteropathy Associated T-cell Lymphoma|NK T-cell Lymphoma|Transformed Mycosis Fungoides June 2016 Phase 2
NCT02713828 PrECOG, LLC.|Celldex Therapeutics Squamous Cell Carcinoma of the Lung April 10, 2016 Phase 1|Phase 2
NCT02423291 Fondazione Italiana Linfomi ONLUS Primary Mediastinal Large B-cell Lymphoma. October 2013 Phase 2
NCT01851200 Fondazione Michelangelo|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Millennium Pharmaceuticals, Inc. Germ Cell Cancer May 2013 Phase 2
NCT01616680 Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|National Cancer Institute (NCI)|Fred Hutchinson Cancer Research Center Graft Versus Host Disease September 2012 Phase 2
NCT03007030 M.D. Anderson Cancer Center|Seattle Genetics, Inc. Lung Diseases Due to External Agents|Mesothelioma April 5, 2017 Phase 2
NCT02939014 Takeda Hodgkin Disease|Lymphoma, Large-Cell, Anaplastic November 30, 2016 Phase 2
NCT01807598 Jason Robert Gotlib|National Cancer Institute (NCI)|Stanford University Aggressive Systemic Mastocytosis|Mast Cell Leukemia|Systemic Mastocytosis September 2013
NCT01671813 H. Lee Moffitt Cancer Center and Research Institute|Seattle Genetics, Inc. Lymphoma March 2013
NCT01578499 Millennium Pharmaceuticals, Inc.|Seattle Genetics, Inc.|Takeda Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma August 2012 Phase 3
NCT01421667 Seattle Genetics, Inc. Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell August 2011 Phase 2
NCT02497131 Fondazione Italiana Linfomi ONLUS Lymphatic Diseases September 2015 Phase 2
NCT02533570 Seattle Genetics, Inc. Systemic Lupus Erythematosus July 2015 Phase 2
NCT01393717 City of Hope Medical Center|National Cancer Institute (NCI) Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma October 20, 2011 Phase 2
NCT02462538 Arbeitsgemeinschaft medikamentoese Tumortherapie ALK+ Anaplastic Large Cell Lymphoma May 2015 Phase 1|Phase 2
NCT01508312 Memorial Sloan Kettering Cancer Center|Seattle Genetics, Inc.|Hôpitaux Universitaires Henri Mondor, France Hodgkin's Lymphoma January 5, 2012 Phase 2
NCT02254239 Mayo Clinic|National Cancer Institute (NCI) Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma February 2016 Phase 1
NCT01396070 Youn Kim|Seattle Genetics, Inc.|Stanford University Non-Hodgkin Lymphoma (NHL)|Cutaneous Lymphoma|Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides|Sezary Syndrome May 2011 Phase 2
NCT01596218 Massachusetts General Hospital|Seattle Genetics, Inc.|Dana-Farber Cancer Institute Graft vs. Host Disease July 2012 Phase 1
NCT02227433 Fondazione Italiana Linfomi ONLUS Hodgkin Lymphoma September 2014 Phase 2
NCT02429375 Memorial Sloan Kettering Cancer Center|MethylGene Inc. Hodgkin Lymphoma April 2015 Phase 1|Phase 2
NCT01026233 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin January 2010 Phase 1
NCT01909934 Millennium Pharmaceuticals, Inc.|Takeda Anaplastic Large-cell Lymphoma October 2013 Phase 4
NCT01703949 University of Washington|National Cancer Institute (NCI) CD30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma March 20, 2013
NCT01657331 Owen A. O'Connor|Columbia University Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma July 2012 Phase 1|Phase 2
NCT01780662 National Cancer Institute (NCI) Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Refractory Childhood Hodgkin Lymphoma January 31, 2013 Phase 1|Phase 2
NCT02581631 Bristol-Myers Squibb|Seattle Genetics, Inc. Non-Hodgkin's Disease December 18, 2015 Phase 1|Phase 2
NCT01461538 Seattle Genetics, Inc. Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Anemia, Refractory, With Excess of Blasts|Solid Tumors October 2011 Phase 2
NCT01700751 Washington University School of Medicine Leukemia, Acute Myeloid|Leukemia, Lymphoblastic,Acute|Myelodysplastic Syndromes February 25, 2013 Phase 1
NCT02244021 Fondazione Italiana Linfomi ONLUS Relapsed/Refractory Hodgkin's Lymphoma December 2014 Phase 2
NCT01805037 Northwestern University|Seattle Genetics, Inc. Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II G March 2013 Phase 1|Phase 2
NCT02780011 The Methodist Hospital System|Millennium Pharmaceuticals, Inc. CD30-positive Lymphoma|CD30-positive Solid Tumor September 2016 Phase 1
NCT02572167 Seattle Genetics, Inc.|Bristol-Myers Squibb Hodgkin Lymphoma October 2015 Phase 1|Phase 2
NCT01874054 Seattle Genetics, Inc. Hodgkin Disease June 2013 Phase 1|Phase 2
NCT02729961 University of Washington|National Cancer Institute (NCI) Anaplastic Large Cell Lymphoma, ALK-Positive|Systemic Anaplastic Large Cell Lymphoma June 2017 Phase 1|Phase 2
NCT03187210 University Hospital Inselspital, Berne|Mundipharma Medical Company Lymphoma June 2017 Phase 1|Phase 2
NCT02096042 M.D. Anderson Cancer Center|Seattle Genetics, Inc. Leukemia April 2014 Phase 1|Phase 2
NCT02979522 Millennium Pharmaceuticals, Inc.|Takeda Hodgkin Disease July 1, 2017 Phase 1
NCT02487979 National Cancer Institute (NCI) Recurrent Osteosarcoma February 16, 2016 Phase 2
NCT02169505 M.D. Anderson Cancer Center Lymphoma May 2015 Phase 2
NCT01902160 National Cancer Institute (NCI) Recurrent Adult Hodgkin Lymphoma September 2013 Phase 1
NCT02758717 Academic and Community Cancer Research United|National Cancer Institute (NCI) Classical Hodgkin Lymphoma|Stage IB Hodgkin Lymphoma|Stage II Hodgkin Lymphoma|Stage IIA Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage III Hodgkin Lymphoma|Stage IIIA Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IV Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma May 2016 Phase 2
NCT03057795 City of Hope Medical Center|National Cancer Institute (NCI) Classical Hodgkin Lymphoma|Hematopoietic Cell Transplantation Recipient|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma April 3, 2017 Phase 2
NCT01992653 Genentech, Inc. Lymphoma, Non Hodgkin November 2013 Phase 1|Phase 2
NCT02302339 Celldex Therapeutics Melanoma November 2014 Phase 2
NCT02552121 Genmab Ovary Cancer|Cervix Cancer|Endometrium Cancer|Bladder Cancer|Prostate Cancer (CRPC)|Esophagus Cancer|Lung Cancer (NSCLC) October 2015 Phase 1|Phase 2
NCT01290549 Genentech, Inc. Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia March 22, 2011 Phase 1
NCT02988843 Masonic Cancer Center, University of Minnesota Germ Cell Tumor March 29, 2017 Phase 2
NCT01620229 Fred Hutchinson Cancer Research Center|Seattle Genetics, Inc.|National Cancer Institute (NCI) Hematopoietic/Lymphoid Cancer June 2013 Phase 1|Phase 2
NCT02363283 National Cancer Institute (NCI) Recurrent Uveal Melanoma|Stage IV Uveal Melanoma September 16, 2015 Phase 2
NCT01830777 Massachusetts General Hospital Acute Myelogenous Leukemia May 2013 Phase 1
NCT02616965 Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation Cutaneous T-cell Lymphoma (CTCL) February 22, 2017 Phase 1
NCT02744612 City of Hope Medical Center|National Cancer Institute (NCI)|Pharmacyclics LLC. Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma June 2016 Phase 2
NCT02086604 Washington University School of Medicine Lymphoma, Large B-Cell, Diffuse September 18, 2014 Phase 1
NCT02684292 Merck Sharp & Dohme Corp. Hodgkin Lymphoma May 23, 2016 Phase 3
NCT02298257 The Lymphoma Academic Research Organisation HIV Infection|HIV-associated Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma June 2015 Phase 2
NCT03013933 City of Hope Medical Center|National Cancer Institute (NCI) Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma March 8, 2017 Phase 1
NCT02505269 Massachusetts General Hospital|Seattle Genetics, Inc. Hodgkin Lymphoma July 2015 Phase 2
NCT02689219 Costantine Albany|Indiana University Germ Cell Tumors|Testis Cancer|Testicular Cancer|Embryonal Carcinoma|Nonseminomatous Germ Cell Tumor March 9, 2016 Phase 2
NCT01771107 National Cancer Institute (NCI) AIDS-Related Hodgkin Lymphoma|CD30-Positive Neoplastic Cells Present|Classical Hodgkin Lymphoma|HIV Infection|Stage II Hodgkin Lymphoma|Stage IIA Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage III Hodgkin Lymphoma|Stage IIIA Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IV Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma March 7, 2013 Phase 1|Phase 2
NCT02191930 University of Cologne Hodgkin Lymphoma September 2015 Phase 2
NCT02139592 Takeda Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma April 2014
NCT01896999 National Cancer Institute (NCI) Classical Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma January 24, 2014 Phase 1
NCT02001623 Genmab Ovary Cancer|Cervix Cancer|Endometrium Cancer|Bladder Cancer|Prostate Cancer (CRPC)|Esophagus Cancer|Lung Cancer(NSCLC)|Squamous Cell Carcinoma of the Head and Neck (SCCHN) November 2013 Phase 1|Phase 2
NCT02227199 University of Washington|National Cancer Institute (NCI) Recurrent Adult Hodgkin Lymphoma|Refractory Hodgkin Lymphoma October 10, 2014 Phase 1|Phase 2
NCT02594163 Seattle Genetics, Inc. Diffuse Large B-cell Lymphoma Refractory|Follicular B-cell Non-Hodgkin's Lymphoma October 2015 Phase 2
NCT00866047 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin March 2009 Phase 2
NCT01578967 UNC Lineberger Comprehensive Cancer Center|Seattle Genetics, Inc. Hodgkin Lymphoma, Adult April 2012
NCT01060904 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin January 2010 Phase 1
NCT02275598 University of Modena and Reggio Emilia|Millennium Pharmaceuticals, Inc. Hodgkin Lymphoma April 2013 Phase 2
NCT02623920 University of Arizona Diffuse Large B Cell Lymphoma|Mediastinal Large B-cell Lymphoma|Grey Zone Lymphoma|High Grade B Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma December 16, 2015 Phase 2
NCT02280993 Marjolein Spiering|Millennium: The Takeda Oncology Company|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Hodgkin Lymphoma|Refractory|Relapse May 2014 Phase 1
NCT01196208 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell, Cutaneous
NCT01691898 Genentech, Inc. Follicular Lymphoma, Diffuse Large B-Cell Lymphoma September 26, 2012 Phase 1|Phase 2
NCT01100502 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin April 2010 Phase 3
NCT01026415 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Carcinomas|Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Neoplasms December 2009 Phase 1
NCT01979536 National Cancer Institute (NCI) Anaplastic Large Cell Lymphoma, ALK-Positive|CD30-Positive Neoplastic Cells Present|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma November 8, 2013 Phase 2
NCT01716806 Seattle Genetics, Inc.|Bristol-Myers Squibb Hodgkin Disease October 2012 Phase 2
NCT02927769 Bristol-Myers Squibb Hodgkin Disease March 27, 2017 Phase 2
NCT02298283 The Lymphoma Academic Research Organisation Hodgkin Lymphoma April 2015 Phase 2
NCT01994850 Abramson Cancer Center of the University of Pennsylvania CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Positive Diffuse Large B-cell Lymphoma or CD30 Positive Grey Zone Lymphoma November 2013 Phase 1|Phase 2
NCT02822586 Virginia Commonwealth University|Seattle Genetics, Inc. Mycosis Fungoides|Sézary Syndrome December 19, 2016 Phase 1
NCT02611323 Hoffmann-La Roche Non-Hodgkin's Lymphoma March 9, 2016 Phase 1
NCT00848926 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin February 2009 Phase 2
NCT02686346 The Lymphoma Academic Research Organisation|Millennium Pharmaceuticals, Inc. Hodgkin Disease March 2016 Phase 1|Phase 2
NCT01309789 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Lymphoma, Large-Cell, Anaplastic|Lymphoma, NK-cell|Lymphoma, T-cell February 2011 Phase 1
NCT03113500 City of Hope Medical Center|National Cancer Institute (NCI) Adult T-Cell Leukemia/Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Angioimmunoblastic T-Cell Lymphoma|CD30-Positive Neoplastic Cells Present|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage III Anaplastic Large Cell Lymphoma|Stage IV Anaplastic Large Cell Lymphoma May 25, 2017 Phase 2
NCT02600897 Hoffmann-La Roche Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma March 23, 2016 Phase 1|Phase 2
NCT02734771 Patrick Reagan|Seattle Genetics, Inc.|University of Rochester Diffuse Large B-Cell Lymphoma June 2016 Phase 2
NCT01534078 Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|H. Lee Moffitt Cancer Center and Research Institute|Seattle Genetics, Inc. Hodgkin Lymphoma March 2012 Phase 2
NCT00947856 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin July 2009 Phase 2
NCT01777152 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Anaplastic Large-Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Lymphoma January 2013 Phase 3
NCT03138499 Bristol-Myers Squibb Hodgkin's Disease June 1, 2017 Phase 3
NCT02166463 National Cancer Institute (NCI) Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma March 16, 2015 Phase 3
NCT01925612 Seattle Genetics, Inc. Lymphoma, B-cell|Lymphoma, Large B-cell, Diffuse August 2013 Phase 2
NCT02292979 The Lymphoma Academic Research Organisation|Millennium Pharmaceuticals, Inc. Hodgkin Lymphoma March 2015 Phase 2
NCT02257567 Hoffmann-La Roche Lymphoma October 15, 2014 Phase 1|Phase 2
NCT03067935 Celldex Therapeutics Metastatic gpNMB Expressing Triple Negative Breast Cancer
NCT02243436 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Millennium Pharmaceuticals, Inc. CLASSICAL HODGKIN LYMPHOMA November 2014 Phase 1|Phase 2
NCT01352520 M.D. Anderson Cancer Center|Seattle Genetics, Inc. CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma|Lymphoma, Primary Cutaneous Anaplastic Large Cell|Lymphomatoid Papulosis|Mycosis Fungoides|Skin Lymphoma|Cutaneous Lymphomas|Lymphoma|Hematologic Disorder June 2011 Phase 2
NCT01868451 Memorial Sloan Kettering Cancer Center|Seattle Genetics, Inc.|University of Rochester|City of Hope Medical Center|Stanford University Hodgkin Lymphoma May 2013
NCT02729896 Hoffmann-La Roche Lymphoma November 9, 2016 Phase 1
NCT01920932 St. Jude Children's Research Hospital|Seattle Genetics, Inc. Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma August 12, 2013 Phase 2
NCT01476410 Northwestern University|Robert H. Lurie Cancer Center|Seattle Genetics, Inc. Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma November 2011 Phase 2
NCT02499627 Fondazione Italiana Linfomi ONLUS Lymphatic Diseases October 2015 Phase 2
NCT01997333 Celldex Therapeutics Metastatic gpNMB Over-expressing Triple Negative Breast Cancer November 2013 Phase 2
NCT02098512 New York Medical College|St. Baldrick's Foundation Hodgkin Lymphoma March 2014 Phase 1|Phase 2
NCT01712490 Millennium Pharmaceuticals, Inc.|Seattle Genetics, Inc.|Takeda Hodgkin Lymphoma November 2012 Phase 3
NCT02467946 Centre Antoine Lacassagne|Millennium: The Takeda Oncology Company Clinical Efficacy|Safety July 2015 Phase 1|Phase 2
NCT02398240 Mitchell Cairo|New York Medical College Hodgkin Lymphoma May 2015 Phase 2
NCT00430846 Seattle Genetics, Inc. Lymphoma, Non-Hodgkin|Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic November 2006 Phase 1
NCT00649584 Seattle Genetics, Inc. Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin March 2008 Phase 1
NCT01832116 University Medical Center Groningen|VU University Medical Center|Genentech, Inc. Ovarian Neoplasms|Ovarian Diseases|Adnexal Diseases|Pancreatic Neoplasms|Digestive System Neoplasms|Digestive System Diseases|Pancreatic Diseases March 2013 Phase 1
NCT02408042 Western Regional Medical Center Lymphoma|Hodgkin's Lymphoma|Non-hodgkin's Lymphoma April 2015 Phase 1|Phase 2
NCT01569204 University of Cologne Hodgkin Lymphoma October 2012 Phase 2
NCT02453594 Merck Sharp & Dohme Corp. Hodgkin Lymphoma June 2015 Phase 2
NCT02661503 University of Cologne Classical Hodgkin Lymphoma July 2016 Phase 3
NCT01363947 Genentech, Inc. Non-Small Cell Lung Cancer, Ovarian Cancer June 14, 2011 Phase 1
NCT02391038 Millennium Pharmaceuticals, Inc.|Takeda Advanced Gastrointestinal Carcinoma|Gastroesophageal Junction Adenocarcinoma|Recurrent Gastric Adenocarcinoma|Recurrent Gastroesophageal Junction Adenocarcinoma|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Recurrent Gastrointestinal Carcinoma December 2014 Phase 1
NCT02175433 Agensys, Inc.|Astellas Pharma Inc Relapsed Lymphoid Malignancy|Refractory Lymphoid Malignancy October 14, 2014 Phase 1
NCT02091999 Agensys, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc Metastatic Urothelial Cancer and Other Malignant Solid Tumors June 4, 2014 Phase 1
NCT01963052 Agensys, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc Metastatic Urothelial Cancer November 14, 2013 Phase 1
NCT01577758 Millennium Pharmaceuticals, Inc.|Takeda Advanced Gastrointestinal Malignancies June 2012 Phase 1
NCT01469793 Genentech, Inc. Ovarian Cancer November 2011 Phase 1
NCT02453087 Hoffmann-La Roche Non-Hodgkin's Lymphoma May 31, 2015 Phase 1
NCT02610062 Agensys, Inc.|Astellas Pharma Inc Acute Myeloid Leukemia April 4, 2016 Phase 1
NCT01166490 Seattle Genetics, Inc.|Agensys, Inc. Gastric Neoplasms|Pancreatic Neoplasms July 2010 Phase 1
NCT02202785 Millennium Pharmaceuticals, Inc.|Takeda Pancreatic Adenocarcinoma July 2, 2014 Phase 2
NCT02202759 Millennium Pharmaceuticals, Inc.|Takeda Adenocarcinoma of the Stomach|Gastroesophageal Junction Expressing Guanylyl Cyclase C August 4, 2014 Phase 2
NCT02951117 AbbVie Multiple Myeloma August 31, 2017 Phase 1
NCT01969643 Seattle Genetics, Inc. Breast Cancer September 2013 Phase 1
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.3928 mL 6.9640 mL 13.9280 mL
5 mM 0.2786 mL 1.3928 mL 2.7856 mL
10 mM 0.1393 mL 0.6964 mL 1.3928 mL
Cell Assay
[2]

Monomethyl auristatin E is reconstituted in DMSO.

Monomethyl auristatin E (MMAE, 5 nM) and ionizing radiation (IR) treated cells are harvested and lysed in RIPA buffer with protease and phosphatase inhibitors. Thirty μg of lysate undergo electrophoresis using 4-12% Bis-Tris gels, transferred to PVDF membranes and incubated with indicated primary antibodies. Blots are developed by ECL.

Animal Administration
[2]

Mice[2]
6-8 week old female athymic nu/nu mice are injected subcutaneously into thighs with 5×106 HCT-116 or PANC-1 cells in a 1:1 Matrigel and PBS solution. Mice are treated with IR or intravenous (IV) injection of ACPP-cRGD-MMAE (6 nmoles/day, 18 nmoles total, i.v.), tumor tissue is harvested, formalin fixed and paraffin embedded followed by staining with indicated antibodies. The primary antibody is used at a 1:250 dilution and is visualized using DAB as a chromagen with the UltraMap system.

References
M.Wt

717.98

Formula

C₃₉H₆₇N₅O₇

CAS No.

474645-27-7

Storage

-20°C, protect from light, stored under nitrogen

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 48 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.76%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Monomethyl auristatin E
Cat. No.:
HY-15162
Quantity: